Profusa, Inc.

Profusa, Inc. shareholders approved all proposals at the 2026 Annual Meeting, including the authorization for the planned acquisition of the PanOmics™ multi-omics diagnostics platform. They also approved debt conversion matters to strengthen the balance sheet and authorized a reverse stock split to maintain Nasdaq listing compliance. These approvals provide Profusa with important tools to advance strategic initiatives, strengthen its capital structure, and position the company for future growth.

Profusa, Inc. announced the submission of its response package to GMED, its European Notified Body, for the Lumee® Oxygen Platform's MDR conformity assessment. This action follows successful Stage 1 and Stage 2 assessments and is a crucial step towards obtaining CE Mark certification, enabling commercialization in Europe. The submission included updates to technical documentation, quality system evidence, clinical evaluation, and validation information. While CEO Ben Hwang highlighted this as a significant milestone, the company noted that the timing and outcome of GMED's review remain uncertain.

Profusa, Inc. has submitted an Advance Notice to Ascent Partners Fund LLC to draw on its equity line of credit. For notices issued between June 8 and July 15, 2026, the company agreed to modified terms, including a purchase cap of 9.99% of outstanding shares (up to $200,000 per notice) and immediate funding upon share delivery. A price adjustment mechanism, or "True-Up Mechanism," was also included, which could result in the issuance of additional shares to Ascent.

Profusa, Inc. will hold its Annual Meeting on June 23, 2026, to vote on several significant corporate actions. Key proposals include approving a reverse stock split (1-for-5 to 1-for-200) to regain Nasdaq listing compliance and authorizing the issuance of convertible preferred stock to Bio Insights LLC for the acquisition of PanOmics Assay assets. Stockholders will also consider approving the potential issuance of common stock upon conversion of a promissory note, amending the 2025 Equity and Incentive Plan to increase available shares, and electing a Class I director. The Board of Directors recommends voting "FOR" all proposals.

Profusa Inc. and Bio Insights LLC have executed a First Amendment to their Asset Purchase Agreement, originally dated April 21, 2026. The amendment primarily removes Section 4.6, which had stipulated the issuance of an aggregate 12% of Profusa's fully diluted common stock to its Chief Executive Officer and Chief Financial Officer for retention purposes. The original agreement, valued at $30,000,000, involves Profusa acquiring substantially all of Bio Insights' know-how assets related to its PanOmics Assay platform, to be paid in Series A Convertible Preferred Stock.

Profusa, Inc. submitted an Advance Notice to Ascent Partners Fund LLC on May 18, 2026, requesting the purchase of common stock under their existing equity line of credit. The agreement for May 2026 Advance Notices specifies that Ascent will purchase up to 9.99% of outstanding shares, with a $300,000 cap per notice. Ascent will fund 97% of the lowest VWAP from the prior ten trading days upon share delivery, and a True-Up Mechanism is included for potential price adjustments.

Profusa, Inc. reported a net loss of $3.5 million for the first quarter of 2026 and a significant working capital deficit of $28.4 million, raising substantial doubt about its ability to continue as a going concern. Despite facing Nasdaq delisting notices for failing to meet market value and minimum bid price requirements, the company successfully appealed and received continued listing relief. Profusa continues to rely on its Equity Line of Credit and PIPE Subscription Agreement for financing, with $88.9 million and $10.5 million available, respectively, to fund its operations and product development.

Profusa, Inc. announced its listing on The Nasdaq Capital Market, effective May 15, 2026. This move represents the first in a series of interim milestones established by the Nasdaq Hearings Panel. The purpose of these steps is to ensure Profusa's continued compliance with Nasdaq's bid price and stockholders' equity requirements for maintaining its listing on the Capital Market tier.

Profusa, Inc. announced that it received a decision letter from the Nasdaq Hearings Panel on May 6, 2026, granting an exception to continue its listing on Nasdaq. This exception is contingent upon the company meeting specific interim milestones and complying with Nasdaq's Bid Price Rule and Equity Rule by July 6, 2026. Profusa is currently evaluating these conditions and intends to take necessary actions to achieve compliance, though there is no assurance it will be able to do so.

Profusa, Inc. announced that the Nasdaq Hearings Panel approved its request to transfer the listing of its securities from The Nasdaq Global Market to The Nasdaq Capital Market. The company's continued listing on Nasdaq is contingent upon meeting specific interim milestones and achieving compliance with the bid price and stockholders' equity requirements for the Capital Market tier by July 6, 2026.